Health Notices and Amendments




26 JUNE 2014 NEW ZEALAND GAZETTE, No. 68 1921

Product: Advate
Active Ingredient: Octocog alfa 1500IU
Dosage Form: Powder for injection with diluent
New Zealand Sponsor: Baxter Healthcare Limited
Manufacturers: Hameln Pharmaceuticals GmbH, Hameln, Germany
Baxter AG, Vienna, Austria
Baxter Bioscience AG, Neuchatel, Switzerland

Product: DBL™ Docetaxel, Concentrated Injection
Active Ingredient: Docetaxel 10mg/mL
Dosage Form: Solution for infusion
New Zealand Sponsor: Hospira NZ Limited
Manufacturers: Hospira Australia Pty Limited, Melbourne, Australia
Zydus Hospira Oncology Limited (ZHOPL), Gujarat, India

Dated this 20th day of June 2014.

STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

go3887

New Zealand Public Health and Disability Act 2000

Advice Notice to General Practitioners Concerning Patient Benefits and Other Subsidies (Amendment No. 15)

Pursuant to sections 88(1) and (3) of the New Zealand Public Health and Disability Act 2000, and with the approval of the Minister of Health under section 89(3) of that Act, the district health boards listed below give the following notice.

Notice

  1. Title—(1) This notice is the Advice Notice to General Practitioners Concerning Patient Benefits and Other Subsidies (Amendment No. 15).

(2) In this notice, the Advice Notice to General Practitioners Concerning Patient Benefits and Other Subsidies¹ is called the “principal notice”.

  1. Commencement—This notice comes into force on 1 July 2014.

  2. Amendment—Schedule 3 of Part B of the principal notice is amended as follows:

    (a) Clause 4.6 is amended by deleting “$19.59” and replacing it with “$19.79” in both places where it occurs.

    (b) Clause 5.5 is amended by deleting “$19.59” and replacing it with “$19.79”.

    (c) Clause 5.7 is amended by deleting “$19.59” and replacing it with “$19.79”.

  3. Statement of reasons for departure from terms and conditions of the principal notice for purposes of section 89(5) of the New Zealand Public Health and Disability Act 2000—Following Cabinet approval, the subsidised fee for immunisations is increased by 1.00%.

Dated this 22nd day of June 2014.

DR NICK CHAMBERLAIN, Chief Executive.
For and on behalf of the:

NORTHLAND DISTRICT HEALTH BOARD
and as delegate on behalf of the 19 district health boards listed below:

WAIKATO DISTRICT HEALTH BOARD
WAITEMATA DISTRICT HEALTH BOARD
AUCKLAND DISTRICT HEALTH BOARD
COUNTIES MANUKAU DISTRICT HEALTH BOARD
LAKES DISTRICT HEALTH BOARD
BAY OF PLENTY DISTRICT HEALTH BOARD
TAIRAWHITI DISTRICT HEALTH BOARD
TARANAKI DISTRICT HEALTH BOARD
HAWKE’S BAY DISTRICT HEALTH BOARD
WHANGANUI DISTRICT HEALTH BOARD
MIDCENTRAL DISTRICT HEALTH BOARD
HUTT VALLEY DISTRICT HEALTH BOARD
CAPITAL & COAST DISTRICT HEALTH BOARD
WAIRARAPA DISTRICT HEALTH BOARD
NELSON MARLBOROUGH DISTRICT HEALTH BOARD



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2014, No 68





✨ LLM interpretation of page content

🏥 Consent to Distribution of New Medicines (continued from previous page)

🏥 Health & Social Welfare
20 June 2014
Medicines, Distribution, Advate, Octocog alfa, Baxter Healthcare Limited, DBL™ Docetaxel, Docetaxel, Hospira NZ Limited
  • STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health

🏥 Advice Notice to General Practitioners Concerning Patient Benefits and Other Subsidies (Amendment No. 15)

🏥 Health & Social Welfare
22 June 2014
Patient Benefits, Subsidies, Immunisations, General Practitioners, District Health Boards
  • DR NICK CHAMBERLAIN, Chief Executive